MARKET

RVNC

RVNC

Revance Therapeu
NASDAQ
25.20
+0.26
+1.04%
Opening 14:38 09/29 EDT
OPEN
24.93
PREV CLOSE
24.94
HIGH
25.20
LOW
23.59
VOLUME
791.95K
TURNOVER
12.29M
52 WEEK HIGH
29.58
52 WEEK LOW
11.27
MARKET CAP
2.04B
P/E (TTM)
-6.5594
1D
5D
1M
3M
1Y
5Y
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
Upgrades
Benzinga · 09/22 14:41
What 6 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Benzinga · 09/22 13:09
Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces Price Target of $33
Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.
Benzinga · 09/22 10:20
--Goldman Sachs Reinstates Revance Therapeutics With Buy Rating, $33 Price Target
--Goldman Sachs Reinstates Revance Therapeutics With Buy Rating, $33 Price Target
MT Newswires · 09/22 08:06
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
NASHVILLE, Tenn., September 21, 2022--Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
Business Wire · 09/21 12:00
BRIEF-Revance Announces Two Publications Highlighting Efficacy And Safety Profile Of Daxxify For Injection In Aesthetic Surgery Journal
BRIEF-Revance Announces Two Publications Highlighting Efficacy And Safety Profile Of Daxxify For Injection In Aesthetic Surgery Journal
Reuters · 09/19 12:27
Revance Therapeutics' (NASDAQ:RVNC) investors will be pleased with their respectable 80% return over the last three years
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Simply Wall St. · 09/17 12:36
Insider Sell: Revance Therapeutics
Insider Sell: Revance Therapeutics
MT Newswires · 09/16 17:01
More
About RVNC
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.